Carol Fabian

Director, Breast Cancer Prevention and Survivorship Research Center, Medical Oncology · University of Kansas School of Medicine

Credentials: · · · ·

History

Breast Cancer Prevention and Survivorship Research Center · University of Kansas School of Medicine
Present
Breast Cancer Prevention & Survivorship Centers · City of Hope National Medical Center
Present
University of Kansas School of Medicine
Present

Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer
National Cancer Institute · R01
Contact PI · $4.1M · University of Kansas Medical Center
2021–2027
Breast Cancer Prevention by Letrozole in High Risk Women
National Cancer Institute · R01
Contact PI · $1.8M · University of Kansas Medical Center
2007–2013
Breast Cancer Risk Biomarkers and Energy Balance
National Cancer Institute · R21
Contact PI · $323.4K · University of Kansas Medical Center
2007–2010
FlaxSeed Lignan for Breast Cancer Chemoprevention
National Cancer Institute · R21
Contact PI · $487.7K · University of Kansas Medical Center
2005–2009

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
Principal investigator · Completed
University of Kansas Medical Center
2024–2026
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
Principal investigator · Active not recruiting · Phase 2
University of Kansas Medical Center
2021–2027
Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers
Principal investigator · Completed · Early phase 1
Carol Fabian, MD
2021–2024